Form 8-K - Current report:
SEC Accession No. 0000950170-24-120673
Filing Date
2024-11-04
Accepted
2024-11-04 16:05:08
Documents
11
Period of Report
2024-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20241104.htm   iXBRL 8-K 41716
  Complete submission text file 0000950170-24-120673.txt   158398

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20241104.xsd EX-101.SCH 25828
13 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20241104_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 241423436
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)